SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (64)9/20/2004 10:43:11 AM
From: tuck   of 107
 
>>NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Pfizer Inc (NYSE: PFE - News) and Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET - News) today said the European Medicines Agency (EMEA) has accepted the filing of their marketing authorization application for Macugen(TM) (pegaptanib sodium injection), the first in a new class of medicines for neovascular age-related macular degeneration (AMD). The companies also announced that they have completed the filing of a new drug application for Macugen in Canada, where it has been given priority review, and have begun clinical trials with the medicine in Japan.

The AMD Alliance International estimates that 500,000 new cases of neovascular AMD are diagnosed annually worldwide.(1) The disease is the leading cause of severe vision loss in patients over 50 years of age in the developed world.

Macugen is a pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in the formation of unwanted new blood vessels and increased leakage from blood vessels, two of the primary processes responsible for the vision loss associated with neovascular AMD.

Under the terms of the Pfizer/Eyetech collaboration agreement, Pfizer will market Macugen for the prevention and treatment of diseases of the eye and related conditions outside the United States, and pay Eyetech a royalty on net sales. The two companies will co-market the drug in the United States. Macugen is currently under priority review with the U.S. Food and Drug Administration.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News